Karuna Kumar: Busting the Myth about Increasing Infection Risk by IV Iron
Karuna Kumar, Senior Consultant at Yashoda Hospitals, shared a post on LinkedIn about a recent article by Paul W. Foley et al, published in European Journal of Heart Failure, adding:
“One concern I hear from colleagues about IV iron:
‘Doesn’t it increase infection risk? Iron feeds bacteria.’
Fair question. The theory makes sense. Iron is essential for bacterial growth. Give IV iron, maybe you’re feeding pathogens.
The IRONMAN trial just addressed this directly.
They looked at heart failure patients who received IV ferric derisomaltose vs standard care. Specifically tracked serious infections.
The finding?
No increased infection risk.
In fact, there was a trend toward fewer infections in the IV iron group. Not statistically significant, but certainly not worse.
The explanation:
Correcting iron deficiency actually improves immune function. Iron-deficient patients are more susceptible to infections, not less.
My practice hasn’t changed. I’ve been comfortable with IV iron for years. But now I have better data to share with patients who ask.
Based on current evidence, the infection concern appears to be theoretical rather than clinical. More data from other populations will help confirm.
Source:
Eur J Heart Fail 2025 (IRONMAN trial)”
Title: Effect of Correcting Iron Deficiency on the Risk of Serious Infection in Heart Failure: Insights from the IRONMAN Trial
Authors: Paul W. Foley, Paul R. Kalra, John G.F. Cleland, Mark C. Petrie, Philip A. Kalra, Ian Squire, Philip Campbell, Callum Chapman, Patrick Donnelly, Fraser Graham, Andrew Hannah, Ninian N. Lang, Iain Matthews, Stephen J. Leslie, Pierpaolo Pellicori, Sue Piper, Robin Ray, Hernry O. Savage, Chales Spencer, John Walsh, Yuk-Ki Wong, Ian Ford
Stay updated with Hemostasis Today.
-
Apr 22, 2026, 16:16Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up
-
Apr 22, 2026, 15:47Mohammed Alo: Being Fit Does Not Protect You from High LDL
-
Apr 22, 2026, 15:28ASH Committee Brings the Voice of Hematology to Capitol Hill
-
Apr 22, 2026, 15:22Stephen Pendergast: Are Universal Shelf Stable Blood Substitutes Finally Within Reach?
-
Apr 22, 2026, 14:51Mavis Agnes Kisakye: Reconnecting to Drive the Global Bleeding Disorders Agenda Forward
-
Apr 22, 2026, 14:48Augustina Isioma Ikusemoro: Not Every Antigen Speaks Loudly, But the Right Test Will Hear It
-
Apr 22, 2026, 14:46David Brown: Charting a New Path Forward for One Patient Facing Extraordinary Cardiac Challenges
-
Apr 22, 2026, 14:45Ney Carter Borges: Syphilis and Cardiovascular Risk – A Silent and Progressive Vascular Burden
-
Apr 22, 2026, 14:44Sanjay Ahuja Appointed CEO and Medical Director of Innovative Hematology